Abstract: The present invention concerns methods for the treatment of diffuse large cell lymphoma by administration of an anti-CD20 antibody and chemotherapy. Particular embodiments include the administration of anti-CD20 antibody in combination with chemotherapy comprising CHOP (cyclophosphamide, hydroxydaunorubicin/doxorubicin, vincristine, and prednisone/prednisolone) and/or in combination with a transplantation regimen.
Type:
Grant
Filed:
October 3, 2013
Date of Patent:
September 2, 2014
Assignee:
Biogen Idec Inc.
Inventors:
Christine A. White, Antonio J. Grillo-Lopez
Abstract: The present invention relates to methods of diagnosing, and methods of treating, hepatocellular carcinoma in a subject. The invention also relates to antagonists of PLVAP proteins, such as antibodies that specifically bind PLVAP proteins, as well as compositions and kits comprising antagonists of PLVAP proteins. The invention further relates to humanized antibodies that specifically bind PLVAP protein.
Abstract: Monoclonal antibodies that specifically bind to an extracellular domain of human Jagged 1 and inhibit growth of a tumor comprising cancer stem cells are described. Also described is a method of treating cancer that comprises administering a therapeutically effective amount of a monoclonal anti-Jagged 1 antibody.
Abstract: The present invention relates to binding proteins that bind to HER-3 and polynucleotides encoding the same. Expression vectors and host cells comprising the same for the production of the binding protein of the invention are also provided. In addition, the invention provides compositions and methods for diagnosing and treating diseases associated with HER-3 mediated signal transduction and/or its ligand heregulin.
Type:
Grant
Filed:
April 15, 2010
Date of Patent:
July 8, 2014
Assignees:
U3 Pharma GmbH, Amgen, Inc.
Inventors:
Mike Rothe, Martin Treder, Susanne Hartmann, Daniel J. Freeman, Robert Radinsky, Eric Borges
Abstract: The invention relates to a method of preparing heteromultimeric polypeptides such as bispecific antibodies, bispecific immunoadhesins and antibody-immunoadhesin chimeras. The invention also relates to the heteromultimers prepared using the method. Generally, the method provides a multispecific antibody having a common light chain associated with each heteromeric polypeptide having an antibody binding domain. Additionally the method further involves introducing into the multispecific antibody a specific and complementary interaction at the interface of a first polypeptide and the interface of a second polypeptide, so as to promote heteromultimer formation and hinder homomultimer formation; and/or a free thiol-containing residue at the interface of a first polypeptide and a corresponding free thiol-containing residue in the interface of a second polypeptide, such that a non-naturally occurring disulfide bond is formed between the first and second polypeptide.
Type:
Grant
Filed:
September 29, 2006
Date of Patent:
July 1, 2014
Assignee:
Genentech, Inc.
Inventors:
W. Robert Arathoon, Paul J. Carter, Anne M. Merchant, Leonard G. Presta
Abstract: The present invention relates to a method of diagnosis and therapy of cancers expressing the HER2 receptor. The invention provides antibodies or fragments thereof that recognise an epitope of the HER2 receptor truncated form CTF-611, said epitope being defined by a sequence included in SEQ ID NO: 2, and that are capable of discriminating between CTF-611 and CTF-616 (represented by SEQ ID NO:7), preferably additionally capable of discriminating between CTF-611 and CTF-613 (represented by SEQ ID NO:6). The invention also provides a method of cancer diagnosis using the disclosed antibodies, which comprises the detection of the presence of the HER2 receptor truncated form consisting of the amino acid sequence SEQ ID NO: 1 in a patient sample.
Type:
Grant
Filed:
December 6, 2010
Date of Patent:
June 3, 2014
Assignees:
Fundacio Privada Institucio Catalana de Recerca i Estudis Avancats, Fundacio Privada Institut d'Investigacio Oncologica de vall d'Hebron
Inventors:
Joaquin Arribas Lopez, Kim Pedersen, Pier-Davide Angellini, Josep Lluis Parra Palau, Jose Baselga Torres
Abstract: This invention provides antibodies immunologically specific for human ARL-1 (also referred to AKR1B10), a species of the aldo-keto reductase superfamily of proteins. The invention also provides methods of making and methods of using said antibodies.
Type:
Grant
Filed:
January 31, 2011
Date of Patent:
April 1, 2014
Assignee:
The Board of Trustees of Southern Illinois University
Abstract: The present invention relates to live attenuated bacteria of the species Pasteurella multocida, to live attenuated vaccines comprising such live attenuated bacteria, to the use of such bacteria for the manufacture of such vaccines, to methods for the preparation of such vaccines and to diagnostic tests for the detection of such bacteria.
Type:
Grant
Filed:
December 21, 2005
Date of Patent:
November 13, 2012
Assignee:
Intervet International B.V.
Inventors:
Yugang Luo, Paul Vermeij, Antonius Arnoldus Christiaan Jacobs
Abstract: Purified cellobiohydrolase I (glycosyl hydrolase family 7 (Cel7A)) enzymes from Penicillium funiculosum demonstrate a high level of specific performance in comparison to other Cel7 family member enzymes when formulated with purified EIcd endoglucanase from A. cellulolyticus and tested on pretreated corn stover. This result is true of the purified native enzyme, as well as recombinantly expressed enzyme, for example, that enzyme expressed in a non-native Aspergillus host. In a specific example, the specific performance of the formulation using purified recombinant Cel7A from Penicillium funiculosum expressed in A. awamori is increased by more than 200% when compared to a formulation using purified Cel7A from Trichoderma reesei.
Type:
Grant
Filed:
October 8, 2008
Date of Patent:
October 9, 2012
Assignee:
Alliance for Sustainable Energy, LLC
Inventors:
William S. Adney, John O. Baker, Stephen R. Decker, Yat-Chen Chou, Michael E. Himmel, Shi-You Ding
Abstract: Diphtheria and Pseudomonas infections are very common worldwide. The toxins involved in the pathogenesis of those diseases act by inactivating the elongation factor-2 (EF-2), therefore blocking protein synthesis and leading to cell death. Diphthamide formation on EF-2 is a prerequisite step in the inactivation of EF-2, and Dph proteins have been identified as modulating this process. The present application concerns Dph2 deletion mutant genes and proteins and their uses in vitro and in vivo.
Abstract: The present invention provides a vaccine adjuvant consisting of a combination of a surfactant i.e. dimethyldeoctadecylammonium-bromide/chloride (DDA) and a lipid extract from Mycobacterium bovis BCG. The total lipid extract contains both apolar lipids, polar lipids, and lipids of intermediate polarity of which the apolar lipids were found to induce the most powerful immune responses. The total lipids may be extracted with chloroform/methanol and re-dissolved in water before the addition of surfactant. This preparation may be used to induce prominent cell-mediated immune responses in a mammal in order to combat pathogens, or as a treatment for cancer.
Type:
Grant
Filed:
April 8, 2011
Date of Patent:
August 14, 2012
Assignee:
Statens Serum Institut
Inventors:
Else Marie Agger, Peter Andersen, Anja Olsen, Ida Rosenkrands
Abstract: The present invention provides a microorganism belonging to the genus Escherichia in which the activities of glutamine-synthetase adenylyltransferase (GlnE protein) and PII regulatory protein for glutamine synthetase are reduced or lost and which has the ability to form and accumulate L-glutamine or a substance biosynthesized utilizing nitrogen supplied by L-glutamine, and a process for producing L-glutamine or the substance biosynthesized utilizing nitrogen supplied by L-glutamine using the microorganism.
Abstract: A method is disclosed for inducing cell-mediated immunity against cellular antigens. More specifically, the invention provides for a method for inducing cytotoxic T-lymphocyte immunity against weak antigens, notably self-proteins. The method entails that antigen presenting cells are induced to present at least one CTL epitope of the weak antigen and at the same time presenting at least one foreign T-helper lymphocyte epitope. In a preferred embodiment, the antigen is a cancer specific antigen, e.g. PSM, Her2, or FGF8b. The method can be exercised by using traditional polypeptide vaccination, but also by using live attenuated vaccines or nucleic acid vaccination. The invention furthermore provides immunogenic analogues of PSM, Her2 and FGF8b, as well as nucleic acid molecules encoding these analogues. Also vectors and transformed cells are disclosed. The invention also provides for a method for identification of immunogenic analogues of weak or non-immunogenic antigens.
Type:
Grant
Filed:
May 19, 2003
Date of Patent:
October 26, 2010
Assignee:
BN Immunotherapeutics, Inc.
Inventors:
Lucilla Steinaa, Jesper Haaning, Iben Dalum, Peter Birk, Dana Leach, Klaus Gregorius Nielsen, Gunilla Karlsson, Anand Gautam, Søren Mouritsen
Abstract: A method is disclosed for inducing cell-mediated immunity against cellular antigens. More specifically, the invention provides for a method for inducing cytotoxic T-lymphocyte immunity against weak antigens, notably self-proteins. The method entails that antigen presenting cells are induced to present at least one CTL epitope of the weak antigen and at the same time presenting at least one foreign T-helper lymphocyte epitope. In a preferred embodiment, the antigen is a cancer specific antigen, e.g. PSM, Her2, or FGF8b. The method can be exercised by using traditional polypeptide vaccination, but also by using live attenuated vaccines or nucleic acid vaccination. The invention furthermore provides immunogenic analogues of PSM, Her2 and FGF8b, as well as nucleic acid molecules encoding these analogues. Also vectors and transformed cells are disclosed. The invention also provides for a method for identification of immunogenic analogues of weak or non-immunogenic antigens.
Type:
Grant
Filed:
August 11, 2005
Date of Patent:
October 5, 2010
Assignee:
BN Immunotherapeutics, Inc.
Inventors:
Lucilla Steinaa, Søren Mouritsen, Anand Gautam, Iben Dalum, Jesper Haaning, Dana Leach, Klaus Gregorius Nielsen, Gunilla Karlsson, Peter Birk Rasmussen
Abstract: A process is provided for the production of an antibody or a fragment or functionalized fragment thereof using a transformed lower eukaryotic host containing an example DNA sequence encoding the antibody or (functionalized) fragment thereof, wherein the antibody or (functionalized) fragment thereof is derived from a heavy chain immunoglobulin of Camelidae and is devoid of light chains, and wherein the lower eukaryotic host is a mould, preferably belonging to the genera Aspergillus or Trichoderma, or a yeast, preferably belonging to the yeast genera Saccharomyces, Kluyveromyces, Hansenula, or Pichia. The heavy chain fragment can contain at least the whole variable domain. A complementary determining region (CDR) different from the CDR belonging to the natural antibody ex Camelidae can be grafted on the framework of the variable domain of the heavy chain immunoglobulin. The catalytic antibodies can be raised in Camelidae against transition state molecules.
Type:
Grant
Filed:
August 11, 2004
Date of Patent:
September 14, 2010
Assignee:
BAC IP B.V.
Inventors:
Raymond Hamers, Cecile Hamers-Casterman, Serge V. M. Muyldermans, Leon G. J. Frenken, Cornelis T Verrips
Abstract: There are provided methods for screening a library of VHH polypeptides for VHH polypeptides that bind to an antigen including subjecting a library of VHH polypeptides to antigen-affinity selection with the antigen.
Abstract: Heparanase specific molecular probes which can be used for detection of the presence, absence or level of heparanase expression and methods of utilizing same are provided.
Type:
Grant
Filed:
May 24, 2004
Date of Patent:
September 7, 2010
Assignees:
InSight Biopharmaceuticals Ltd., Hadasit Medical Research Services and Development Ltd.
Inventors:
Iris Pecker, Israel Vlodavsky, Yael Friedmann, Tuvia Peretz
Abstract: A method of preparing an antibody- or antibody fragment-targeted cationic immunoliposome or polymer complex comprises the steps of (a) preparing an antibody or antibody fragment; (b) mixing said antibody or antibody fragment with a cationic liposome to form a cationic immunoliposome or with a cationic polymer to form a polyplex; and (c) mixing said cationic immunoliposome or said polyplex with a therapeutic or diagnostic agent to form said antibody- or antibody fragment-targeted cationic immunoliposome or polymer complex.
Abstract: High affinity antibody antagonists of human interleukin-13 receptor alpha 1 are disclosed. The antibody molecules are effective in the inhibition of IL-13R?1-mediated activities and, accordingly, present desirable antagonists for the use in the treatment of conditions associated with hIL-13R?1 activity. The present invention also discloses nucleic acid encoding said antibody molecules, vectors, host cells, and compositions comprising the antibody molecules. Methods of using the antibody molecules for inhibiting or antagonizing IL-13R?1-mediated activities are also disclosed.
Type:
Grant
Filed:
October 19, 2007
Date of Patent:
July 13, 2010
Assignees:
Merck & Co., Inc., CSL Limited
Inventors:
Andrew Donald Nash, Manuel Baca, Louis Jerry Fabri, Dennis Zaller, William R. Strohl, Zhiqiang An
Abstract: The present invention is related to antibodies directed to the antigen CD3 and uses of such antibodies. In particular, the present invention provides fully human monoclonal antibodies directed to CD3. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3, are provided. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also provided.
Type:
Grant
Filed:
June 3, 2005
Date of Patent:
June 1, 2010
Assignee:
Novimmune S.A.
Inventors:
Bernard Mach, Yann Dean, Marie Kosco-Vilbois, Greg Elson, Nicolas Fischer, Olivier Leger